The purposes of the Audit Committee (“Committee”) is to provide assistance to the Board of Directors (the “Board”) of Amyris, Inc. (the “Company”) in fulfilling the Board’s oversight of the Company’s accounting and system of internal controls, the quality and integrity of the Company’s financial reports and the independence and performance of the Company’s independent registered public accounting firm (“Independent Auditors”).
In order to fulfill its purpose, the Audit Committee is to:
• oversee the Company’s accounting and financial reporting processes and audits of Company’s consolidated financial statements;
• oversee the Company’s relationship with its independent auditors (“Independent Auditors”), including appointing or changing Company’s auditors and ensuring their independence;
• facilitate communication among the Independent Auditors and the Company’s financial and senior management and the Board; and
• monitor the periodic reviews of the adequacy of the accounting and financial reporting processes and systems of internal control that are conducted by the Independent Auditors and the Company’s financial and senior management.
This charter sets forth the authority and responsibility of the Committee in fulfilling its purpose. While the Committee has the responsibilities and powers set forth in this Charter, it is not the duty of the Committee to plan or conduct audits or to determine that the Company’s financial statements are complete and accurate and are in accordance with generally accepted accounting principles. This is the responsibility of the Company’s management and the Independent Auditors.
• The Audit Committee will consist of three or more members of the Board, with the exact number being determined by the Board. Each member of the Audit Committee shall be an “independent director” as defined under the applicable rules, regulations and listing requirements of the principal stock exchange where the Company’s common stock is listed for trading, as amended from time to time (the “Exchange Rules”), except as may otherwise be permitted by the Exchange Rules;
• At least one member of the Audit Committee must have past employment experience in finance, accounting or financial oversight, as required by the Exchange Rules;
• Each member of the Audit Committee must be able to read and understand fundamental financial statements, including the Company’s balance sheet, income statement and cash flow statement; and
• The Audit Committee members shall be free from any relationship that, in the opinion of the Board, would interfere with the exercise of independent judgment as a Committee member.
All members of the Committee will be appointed by, and will serve at the discretion of, the Board. The Board may appoint a member of the Committee to serve as the chairperson of the Committee (the “Chair”). If the Board does not appoint a Chair, the Committee members may designate a Chair by their majority vote. The Chair will set the agenda for Committee meetings and conduct the proceedings of those meetings.
The principal responsibilities and duties of the Committee in serving the purposes outlined in Section I of this Charter are set forth below. These duties are set forth as a guide with the understanding that the Committee will carry them out in a manner that is appropriate given the Company’s needs and circumstances. The Committee may supplement them as appropriate and may establish policies and procedures from time to time that it deems necessary or advisable in fulfilling its responsibilities.
The Committee will:
Financial Statements and Disclosures
1. Review and discuss with management the Company’s quarterly results and the related earnings press release prior to distribution to the public.
2. Review the Company’s quarterly and annual financial statements, including any report on the Company’s internal control over financial reporting, and any report or opinion by the Independent Auditors.
3. In connection with the Committee’s review of the annual financial statements:
• discuss the financial statements and the results of the Independent Auditors’ audit of the financial statements with the Independent Auditors and management;
• discuss any items required to be communicated by the Independent Auditors in accordance with the applicable requirements of the Public Company Accounting Oversight Board; and
• discuss with the Company’s management and the Independent Auditors the Company’s selection, application and disclosure of critical accounting policies and practices.
4. Recommend to the Board whether the annual financial statements should be included in the Company’s Annual Report on Form 10-K.
5. In connection with the Committee’s review of the quarterly financial statements:
• discuss with the Independent Auditors and the Company’s management the results of the Independent Auditors’ review of the quarterly financial statements and resolve any issue that may arise;
• discuss significant issues, events and transactions and any significant changes regarding accounting principles, practices, policies (internal or external), judgments or estimates with the Company’s management and the Independent Auditors; and
• discuss and assist in resolving any disagreements between the Company’s management and the Independent Auditors regarding financial reporting.
6. Periodically discuss with the Company’s principal accounting officer the function of the Company’s disclosure controls and procedures and any disclosure committee that may be established by the Company. Discuss with the Company’s Chief Executive Officer and Chief Financial Officer their conclusions regarding the effectiveness of the Company’s disclosure controls and procedures.
7. Review and discuss with the Independent Auditors and the Company’s management their periodic reviews of the adequacy of the Company’s accounting and financial reporting processes and systems of internal control, including any significant deficiencies and material weaknesses in their design or operation. In doing so, the Committee shall evaluate the Company’s compliance with Section 404 of the Sarbanes-Oxley Act of 2002, including risk management required thereby.
8. Review any fraud involving management or any employee of the Company with a significant role in the Company’s internal controls over financial reporting that are disclosed to the Committee.
9. Discuss any comments or recommendations of the Independent Auditors outlined in their annual management letter or internal control reports.
10. Periodically consult with the Independent Auditors out of the presence of the Company’s management about internal controls, the fullness and accuracy of the Company’s financial statements and any other matters that the Committee or Independent Auditors believe should be discussed privately with the Committee.
11. Meet separately, periodically, with management and with internal auditors (or other personnel responsible for the internal audit function).
12. Review with management the Company’s major financial risk exposures and the steps management has taken to monitor such exposures, including the Company’s procedures and any related policies, with respect to risk assessment and risk management.
13. Establish procedures for (i) the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing matters, and violations of the Company’s Code of Business Conduct and Ethics or other legal policies or applicable law; and (ii) the confidential, anonymous submission by Company employees of concerns regarding questionable accounting or auditing matters or violations of Company policies or applicable laws (the “Whistleblower Policy”), and any changes therein. Oversee the review of any such complaints and submissions that have been received, including the current status and the resolution if one has been reached.
14. Be directly responsible for the selection, compensation, retention and oversight of the work of the Independent Auditors. The Independent Auditors will report directly to the Committee.
15. Review the continuing independence of the Independent Auditors, including:
• obtaining and reviewing, on an annual basis, a letter from the Independent Auditors describing all relationships between the Independent Auditors and the Company;
• reviewing and discussing with the Independent Auditors their independence, including the nature and scope of any such relationships; and
• taking appropriate action to oversee the independence of the Independent Auditors, including discontinuing any relationships that the Committee believes compromises the independence of the Independent Auditors.
16. Review the Independent Auditors’ audit planning, scope and staffing.
17. Approve the fees and other compensation to be paid to the Independent Auditors, and pre-approve all audit and non-audit related services provided by the Independent Auditors permitted by the Exchange Rules, the rules of the Securities and Exchange Commission (“Commission Rules”) and applicable law or regulation. The Committee may establish pre-approval policies and procedures for the engagement of the Independent Auditors to render services to the Company, including without limitation policies that would allow the delegation of pre-approval authority to one or more members of the Committee, provided that any pre-approval decision is reported to the Committee at its next scheduled meeting.
18. Review and discuss with the Independent Auditors the reports delivered to the Committee by the Independent Auditors regarding:
• critical accounting policies, estimates and practices used;
• alternative treatments of financial information within generally accepted accounting principles that have been discussed with management, the ramifications of the alternatives, and the treatment preferred by the Independent Auditors; and
• other material written communications between the Independent Auditors and the Company’s management, such as any management letter or schedule of unadjusted differences.
19. On a regular basis, review the status of any legal and regulatory matters that could have a significant impact on the Company’s financial statements.
20. Annually prepare a report to the Company’s stockholders for inclusion in the Company’s annual proxy statement as required by the Commission Rules.
21. Review and approve any proposed transaction between the Company and any related party (other than transactions that are subject to review by another independent committee of the Board), as defined by applicable law, the Commission Rules and the Exchange Rules in accordance with the Company’s Related-Party Transactions Policy.
22. Consider waivers of the Code of Business Conduct and Ethics (other than transactions that are subject to review by the Board as a whole or any other committee of the Board), including waivers requested for executive officers and directors (other than where the potential waiver involves a member of the Committee, in which event, such waiver shall be subject to the review of the Board), and retain authority to grant any such waivers.
23. Perform any other activities required by applicable law, rules or regulations, including the Commission Rules and the Exchange Rules, and take such other actions and perform and carry out any other responsibilities and duties delegated to it by the Board or as the Committee deems necessary or appropriate consistent with its purpose.
The Committee, in discharging its responsibilities, may conduct, direct, supervise or authorize studies of, or investigations into, any matter that the Committee deems appropriate, with full and unrestricted access to all books, records, documents, facilities and personnel of the Company. The Committee has the sole authority and right, at the expense of the Company, to retain legal and other consultants, accountants, experts and advisers of its choice to assist the Committee in connection with its functions, including any studies or investigations. The Committee will have the sole authority to approve the fees and other retention terms of such advisers. The Company will provide for appropriate funding, as determined by the Committee, for:
• payment of compensation to any legal and other consultants, accountants, experts and advisers retained by the Committee; and
• ordinary administrative expenses of the Committee that are necessary and appropriate in carrying out its functions.
Meetings of the Committee shall be held at least 4 times each year or more frequently, as determined appropriate by the Committee. The Chair, in consultation with the other member(s) of the Committee, will set the dates, times and places of such meetings. The Chair or any other member of the Committee may call meetings of the Committee by notice in accordance with the Company’s Bylaws.
The Committee will maintain written minutes of its meetings and copies of its actions by written consent, and will cause such minutes and copies of written consents to be filed with the minutes of the meetings of the Board. The Chair will report to the Board from time to time with respect to the activities of the Committee.
Members of the Committee will receive such fees, if any, for their service as Committee members as may be determined by the Board, which may include additional compensation for the Chair.
The Committee may from time to time as it deems appropriate evaluate the Committee’s composition and performance and report to the Board. The Committee also will review and reassess the adequacy of this Charter from time to time, and recommend to the Board any changes the Committee determines are appropriate.
The Company shall make this Charter freely available to stockholders on request and, provided that the Company is subject to the periodic reporting requirements of the Securities Exchange Act of 1934, shall publish it on the Company’s web site.
R. Neil Williams has served as Intuit's Executive Vice President and Chief Financial Officer since January 2008. He is responsible for all financial aspects of Intuit, including corporate strategy and business development, investor relations, financial operations and real estate. Before joining Intuit, Mr. Williams was the Executive Vice President and Chief Financial Officer for Visa U.S.A., Inc. In that role, he led all financial functions for the company and its subsidiaries, including financial planning, business planning and financial monitoring. Williams concurrently served as Chief Financial Officer for Inovant LLC, Visa's global information technology organization, responsible for global transactions processing and technology development. His previous banking experience includes senior financial positions at commercial banks in the Southern and Midwest regions of the United States. Williams, a certified public accountant, received his Bachelor's degree in business administration from the University of Southern Mississippi.
Dr. Duyk is founder and Managing Partner of Circularis LP, a group focused on supporting technology enabled companies that advance the circular economy and promote sustainability as well as resource efficiency. Prior to Circularis Dr. Duyk was the Managing Director and Partner of TPG Alternative & Renewable Technologies/TPG Biotechnology from 2004 to 2017. Prior to TPG Dr. Duyk served on the Board of Directors and was President of Research and Development at Exelixis. Prior to Exelixis, he was one of the founding scientific staff at Millennium Pharmaceuticals and served as Vice President of Genomics. Prior to his tenure at Millennium, Dr. Duyk was an Assistant Professor at Harvard Medical School (HMS) in the Department of Genetics, and an Assistant Investigator of the Howard Hughes Medical Institute (HHMI). While at HMS, Dr. Duyk was a Co-Principal Investigator in the National Institutes of Health (NIH) funded Cooperative Human Linkage Center.
Dr. Duyk holds a PhD and MD from Case Western Reserve University. He completed his medical and fellowship training at the University of California, San Francisco. While at UCSF, Dr. Duyk was a fellow of the Lucille P. Markey Foundation and was awarded a post-doctoral fellowship from HHMI.
Dr. Duyk currently serves on the Board of Directors of Elevance Renewable Sciences, Regen Holdings and Inocucor.
Dr. Duyk is a member of the BOD and the executive committee for the American Society of Human Genetics. In addition he is a trustee of Case Western Reserve University where he Chairs the finance committee and is a member of the Executive committee. He is also a member of the Institute Board of Directors of the Moffitt Cancer Center where he chairs the R&D committee. He has also served as a member of the SAB for Bayer Crop Sciences.
Dr. Fernando Reinach is managing partner of Pitanga Fund, a venture capital fund based in Brazil, since May 2011. From 2001 to May 2010, Dr. Reinach was a General Partner at Votorantim Novos Negócios Ltda. Before joining Votorantim, he was involved in the creation of two companies, Genomic Engenharia Molecular Ltda., a molecular diagnostic laboratory, and .ComDominio S/A, a datacenter company. Dr. Reinach holds a Bachelor of Science degree in biology from the University of São Paulo and a Doctor of Philosophy degree in Cell and Molecular Biology from Cornell University Medical College.